10x Genomics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for 10x Genomics, Inc. (TXG), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TXG insiders buying or selling?
In the last 12 months, 10x Genomics, Inc. insiders reported 0 open-market purchases ($0) and 26 sales ($16.9M) — net selling of $16.9M. Since September 2019, Trabud has recorded 258 Form 4 filings for TXG: 6 buys ($31.2M) and 252 sells ($878.2M).
Source: SEC EDGAR Form 4
What stands out
- No 10x Genomics, Inc. insider made an open-market purchase in the last 12 months; the 26 reported open-market sales totaled $16.9M.
Key Statistics (September 2019 – Sep 24, 2026)
Total Form 4 filings
258
SEC EDGAR
Insider filers
16
Insider buys (6)
$31.2M
Insider sells (252)
$878.2M
Insider sentiment
Net sellingNet insider flow of $847.0M in net selling since September 2019, and $16.9M in net selling over the last 12 months.
Recent TXG insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Shehnaaz Suliman | Director | Sale | 5.7K | $81.19 | $464.7K | SEC ↗ |
| Sep 24, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 25.0K | $81.22 | $2.0M | SEC ↗ |
| Sep 11, 2026 | Adam Taich | Chief Financial Officer | Sale | 46.4K | $64.57 | $3.0M | SEC ↗ |
| Sep 8, 2026 | John R Stuelpnagel | Director | Sale | 20.0K | $61.75 | $1.2M | SEC ↗ |
| Aug 28, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 10.5K | $63.69 | $667.9K | SEC ↗ |
| Aug 26, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 18.5K | $63.02 | $1.2M | SEC ↗ |
| Aug 26, 2026 | Adam Taich | Chief Financial Officer | Sale | 17.2K | $63.02 | $1.1M | SEC ↗ |
| Aug 26, 2026 | Benjamin J. Hindson | Title: President and Chief Scientific Officer | Sale | 13.8K | $63.02 | $870.9K | SEC ↗ |
| Aug 26, 2026 | Shehnaaz Suliman | Director | Sale | 2.2K | $63.65 | $140.5K | SEC ↗ |
| Aug 17, 2026 | Sarah A. Teichmann | Director | Sale | 7.6K | $57.25 | $432.3K | SEC ↗ |
| Aug 13, 2026 | John R Stuelpnagel | Director | Sale | 20.0K | $57.75 | $1.2M | SEC ↗ |
| Jun 24, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 30.0K | $34.44 | $1.0M | SEC ↗ |
| Jun 18, 2026 | Shehnaaz Suliman | Director | Sale | 5.7K | $32.63 | $186.8K | SEC ↗ |
| May 27, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 28.9K | $24.54 | $709.1K | SEC ↗ |
| May 27, 2026 | Benjamin J. Hindson | Title: President and Chief Scientific Officer | Sale | 11.6K | $24.44 | $283.4K | SEC ↗ |
| May 27, 2026 | Adam Taich | Chief Financial Officer | Sale | 15.1K | $24.44 | $369.0K | SEC ↗ |
| Apr 16, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 5.0K | $24.56 | $122.8K | SEC ↗ |
| Mar 25, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 15.0K | $19.26 | $288.9K | SEC ↗ |
| Mar 4, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 16.2K | $22.73 | $367.1K | SEC ↗ |
| Feb 27, 2026 | Sarah A. Teichmann | Director | Sale | 7.6K | $19.41 | $147.1K | SEC ↗ |
| Feb 25, 2026 | Serge Saxonov | Chief Executive Officer | Sale | 9.6K | $18.58 | $178.9K | SEC ↗ |
| Feb 25, 2026 | Adam Taich | Chief Financial Officer | Sale | 9.0K | $18.58 | $166.6K | SEC ↗ |
| Feb 25, 2026 | Benjamin J. Hindson | Title: President and Chief Scientific Officer; Exhibit 24.1 - Power of Attorney | Sale | 7.8K | $18.58 | $145.4K | SEC ↗ |
| Nov 25, 2025 | Adam Taich | Chief Financial Officer | Sale | 11.9K | $19.00 | $225.9K | SEC ↗ |
| Nov 25, 2025 | Benjamin J. Hindson | President and Chief Scientific Officer | Sale | 8.3K | $19.00 | $157.4K | SEC ↗ |
Showing the 25 most recent of 258 Form 4 filings for 10x Genomics, Inc..
Most active TXG insiders
- Serge Saxonov68 filings
- Benjamin J. Hindson47 filings
- John R Stuelpnagel40 filings
- Justin J. Mcanear37 filings
- Bradford Crutchfield30 filings
Ask anything about TXG insider activity
Use Trabud's AI agent to query 10x Genomics, Inc.'s Form 4 history in plain English — "Show me TXG CEO purchases this year" or compare it against any other ticker.
Open the AI agentTXG insider trading FAQ
Are 10x Genomics, Inc. insiders buying or selling?
In the last 12 months, 10x Genomics, Inc. insiders reported 0 open-market purchases ($0) and 26 sales ($16.9M) — net selling of $16.9M. Since September 2019, Trabud has recorded 258 Form 4 filings for TXG: 6 buys ($31.2M) and 252 sells ($878.2M). Over the full record that is net selling of $847.0M.
How many insiders trade TXG stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for 10x Genomics, Inc.. The most recent filing was accepted on Sep 24, 2026.
Where does Trabud get TXG insider trading data?
All TXG insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.